MicroRNA Gene Polymorphisms in Evaluating Therapeutic Efficacy After Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma

Qiu, Guang-Ping; Liu, Jie

doi:10.1089/gtmb.2016.0073

Cited by 9 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, different genetic features such as different expression of polycomb chromobox 4 and x‐ray repair complementing 4 among individuals with hepatocellular carcinoma have been proven to modify MVD, and ultimately lead to unsuccessful pa‐TACE treatment . Genetic changes in a disintegrin and metalloproteinase with thrombospondin motifs 5, microRNA‐1268a, microRNA‐196a, and microRNA‐499a may change individual's response to pa‐TACE treatment and result in treatment failure …”

Section: Discussionmentioning

confidence: 99%

“…(30,32) Genetic changes in a disintegrin and metalloproteinase with thrombospondin motifs 5, microRNA-1268a, microRNA-196a, and microRNA-499a may change individual's response to pa-TACE treatment and result in treatment failure. (15,31) In this study, we are particularly concerned with the association between microRNA-4651 expression in cancerous tissues and pa-TACE treatment, primarily because our previous reports showed a higher serum mciroRNA-4651 level among patients with aflatoxin B1-related hepatocellular carcinoma, and this upregulation significantly correlated with tumor angiogenesis and prognosis. (27,28) This is indicative of its acting as an oncogene or having roles like oncogenes.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, this therapy is being used as an attractive adjuvant therapy (e.g., postoperative TACE [pa‐TACE]) for resectable hepatocellular carcinoma with the hope that it may decrease tumor recurrence and improve survival of patients . On the basis of the currently available clinic evidence, however, pa‐TACE treatment does not display anticancer effects on hepatocellular carcinoma cases with some specific genetic profiles . Thus, it is vital to identify what kinds of hepatocellular carcinoma and characteristics can gain a benefit from pa‐TACE treatment.…”

mentioning

confidence: 99%

“…(10,14) On the basis of the currently available clinic evidence, however, pa-TACE treatment does not display anticancer effects on hepatocellular carcinoma cases with some specific genetic profiles. (15,16) Thus, it is vital to identify what kinds of hepatocellular carcinoma and characteristics can gain a benefit from pa-TACE treatment.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Micro RNA‐4651 Serves as a Potential Biomarker for Prognosis When Selecting Hepatocellular Carcinoma Patients for Postoperative Adjuvant Transarterial Chemoembolization Therapy

Zhang

Huang

et al. 2018

Hepatology Communications

View full text Add to dashboard Cite

Our previous reports have shown that microRNA‐4651 is a potential early diagnostic and prognostic marker for hepatocellular carcinoma. We aimed to investigate whether microRNA‐4651 modified postoperative adjuvant transarterial chemoembolization (pa‐TACE) to improve the prognosis of hepatocellular carcinoma. A hospital‐based retrospective study, including 302 patients with advanced‐stage hepatocellular carcinoma who received tumor resection or tumor resection plus pa‐TACE as an initial therapy, was conducted to assess the effects of microRNA‐4651 on pa‐TACE treatment. MicroRNA‐4651 expression in tumor tissues was tested using the TaqMan‐PCR technique. The sensitivity of tumor cells to doxorubicin (an anticancer drug used in pa‐TACE procedure) was analyzed by the half‐maximal inhibitory concentration (IC50). Upregulated microRNA‐4651 expression in tumor tissues can improve the therapeutic response of patients with hepatocellular carcinoma on pa‐TACE (hazard ratios [95% confidence intervals] = 0.32 [0.22‐0.46] for death risk and 0.39 [0.28‐0.56] for tumor‐recurrence risk, respectively), but downregulated expression cannot. Functional analyses–displayed microRNA‐4651 mimics decreased while its inhibitor increased the IC50 of tumor cells to doxorubicin (0.65 [0.61‐0.69] versus 2.17 [1.98‐2.37] µM). Cytochrome P450 2W1 was shown as a possible target of microRNA‐4651. Additionally, dysregulation of microRNA‐4651 also affected the clinical pathological features of hepatocellular carcinoma and was an independent prognostic factor for this cancer. Conclusion: These results indicate that increasing microRNA‐4651 expression may be beneficial for pa‐TACE in improving hepatocellular carcinoma prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Micro RNA‐4651 Serves as a Potential Biomarker for Prognosis When Selecting Hepatocellular Carcinoma Patients for Postoperative Adjuvant Transarterial Chemoembolization Therapy

Zhang

Huang

et al. 2018

Hepatology Communications

View full text Add to dashboard Cite

show abstract

“…P atients with hepatocellular carcinoma (HCC), including primary tumor and metastasis, can be treated by transcatheter arterial chemoembolization (TACE), absolute alcohol ablation, radiofrequency ablation (RFA), and microwave ablation with certain application effects. 1,2 Particularly, ablative treatments currently represent the first-line option for the treatment of early stage unresectable HCC. 3 The RFA has been widely applied in practice owing to the small trauma and few complications, with high inactivation rate of tumor and low relapse rate.…”

Section: Introductionmentioning

confidence: 99%

The Application Comparison of Contrast-Enhanced Ultrasound and Contrast-Enhanced Computed Tomography in Radiofrequency Ablation Treatment for Hepatocellular Carcinoma

Liu

Wang

Xing

et al. 2019

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Objective: To compare the application value of contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed tomography (CECT) in radiofrequency ablation (RFA) for treatment of hepatocellular carcinoma (HCC). Methods: A total of 112 patients with primary HCC were enrolled for the treatment of RFA and they were randomly equally divided into the CEUS group and CECT group. The gender, age, and number and maximum diameter of tumors between the two groups were compared. The median duration of follow-up was 27.0 months and the clinical outcomes were compared. Results: The average examination time period before ablation, of guiding needle insertion and of ablation in the CEUS group were significantly shorter than those in the CECT group ( p < 0.05). The complete ablation rate of the CEUS group was significantly higher than that of the CECT group (86.36% vs. 73.17%, v 2 = 4.618, p = 0.032). There was no comparative difference in the incidence of complications (including fever, infection, pain, and liver injury) between the two groups ( p > 0.05). The relapse rate of the CEUS group was lower and the survival rate was higher than that in the CECT group ( p < 0.05). Conclusions: Compared with the CECT, the RFA for treatment of HCC guided by the CEUS shorten the time of examination and treatment. The immediate postoperative assessment can improve the overall complete ablation rate, reduce the relapse rate, and increase the survival rate, which provides insights for the clinical application.

show abstract

Up-Regulation of miR-26a-5p Promoted Cell Growth and Tumor Metastasis of Intracranial Malignancy Through Phosphatase and Tensin Homolog Deleted on Chromosome Ten/Phosphatidylinositol3-Kinase/Protein Kinase B Signaling Pathway

2023

j biomater tissue eng

View full text Add to dashboard Cite

Objective: Intracranial malignancy has ranked the 6th and 3rd in terms of global tumor morbidity and mortality, respectively. MicroRNA (miRNA) can regulate the cell physiological process. Methods: In previous study, we explored the anti-cancer effects and mechanism of miR-26a-5p in human glioma. MiR-26a-5p expression was increased in patient with glioma. Up-regulation of miR-26a-5p promoted cell growth and tumor metastasis of human glioma through inactivation of PTEN/PI3K/Akt. Results: Down-regulation of miR-26a-5p reduced cell growth and tumor metastasis of human glioma. Downregulation of miR-26a-5p induced PTEN protein expression, and reduced PI3K and p-Akt protein expression in human glioma. PTEN or PI3K inhibitor reduced the effects of miR-26a-5p on cell growth and tumor metastasis of human glioma. Conclusion: Our findings proved that the cancer effect of MiR-26a-5p regulates PTEN expression and promoted cell growth of human glioma through PI3K/Akt signalling pathway.

show abstract

MicroRNA Gene Polymorphisms in Evaluating Therapeutic Efficacy After Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma

Abstract: MiR-196a2 rs11614913 and miR-499a rs3746444 were significantly associated with a curative effect and a positive prognosis of TACE for primary HCC.

Cited by 9 publications

References 30 publications

Micro RNA‐4651 Serves as a Potential Biomarker for Prognosis When Selecting Hepatocellular Carcinoma Patients for Postoperative Adjuvant Transarterial Chemoembolization Therapy

Micro RNA‐4651 Serves as a Potential Biomarker for Prognosis When Selecting Hepatocellular Carcinoma Patients for Postoperative Adjuvant Transarterial Chemoembolization Therapy

The Application Comparison of Contrast-Enhanced Ultrasound and Contrast-Enhanced Computed Tomography in Radiofrequency Ablation Treatment for Hepatocellular Carcinoma

Up-Regulation of miR-26a-5p Promoted Cell Growth and Tumor Metastasis of Intracranial Malignancy Through Phosphatase and Tensin Homolog Deleted on Chromosome Ten/Phosphatidylinositol3-Kinase/Protein Kinase B Signaling Pathway

Contact Info

Product

Resources

About